Jing Zhou

Jing Medicine is a clinical-stage biopharmaceutical company based in Beijing, China, focused on the discovery and development of innovative small molecule precision medicines for oncology. The company specializes in targeting specific genetic drivers of cancer, particularly in the field of non-small cell lung cancer (NSCLC) and other solid tumors. Its lead programs include next-generation tyrosine kinase inhibitors (TKIs) designed to overcome resistance mutations associated with existing therapies. Jing Medicine aims to provide more effective and safer treatment options for patients with unmet medical needs through its internal R&D capabilities.